Navigation Links
Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
Date:6/24/2013

p>

About B-Cell Activating Factor (BAFF) and Blisibimod

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on the potential positive role on BAFF inhibitors in treating lupus and rheumatoid arthritis with concomitant decreases in B-cells, plasma cells and autoantibodies. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel protein compromised of high-affinity BAFF binding domains fused to a human Fc domain, called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune disorders.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about the Company's expectations with respect to its proposed offering, including its intention to offer and sell shares, its intention to grant the underwriters an option to purchase additional shares and its intended use of proceeds from the offering.  Such statements are based on the Company's e
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Akcea ... (NASDAQ: ISIS ), announced today that the ... Drug Designation to volanesorsen (ISIS-APOCIII Rx ) for ... (FCS).  FCS is a rare genetic disease characterized ... pancreatitis. In a Phase 2 study published in ...
(Date:7/5/2015)... , July 6, 2015 Nihon University ... symposium on Medical-Engineering Collaboration "Medicine Definitely Jumps ... 10, 2015 in Tokyo, Japan ... medical applied research will present their achievements and ... a new industry produced with 8K technology. ...
(Date:7/3/2015)... MUMBAI, India , July 4, 2015 /PRNewswire/ ... médicale continue cible les épidémies que sont l,hypertension, ... centrale et du Sud-Est, par l,intermédiaire de plateformes ... ces maladies.      (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ... Prendre en charge le diabète en ligne , ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3
... Aug. 24 Curemark Founder and CEO Dr. Joan Fallon ... Sequencing 2009 Conference at Harvard Medical School on July 14th. ... this cutting-edge conclave is particularly significant, since epigenetics is the ... a change in the DNA sequence. Presenters at the session ...
... , EMERYVILLE, Calif., Aug. 21 ... NBY ), a clinical stage company developing non-antibiotic anti-infective compounds ... viral, and fungal infections, will deliver two poster presentations at the ... San Francisco, CA. The two poster presentations will describe results ...
Cached Medicine Technology:Curemark CEO Presents at Epigenomics Conference 2NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 2NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 3
(Date:7/4/2015)... ... ... Dating a real millionaire online can be more difficult. Millionairematchapp.com ... to remove the worries from meeting partners. Recently, the site announced they're publishing ... and readers have responded with excitement. , “There's quite a few millionaire dating ...
(Date:7/4/2015)... ... ... When a hacker gains access to someone’s email account, it can lead to all sorts ... the FTC issued a scam alert about a social engineering scam which cons ... reset instigated by the hacker. All they have to do is click for a ...
(Date:7/3/2015)... ... July 03, 2015 , ... Brendon Burchard's new ... buzz of media attention. In an effort to spread the news, a comprehensive ... "These days many people are feeling overwhelmed by stress and fatigue," reports Hendricks. ...
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top ... mesothelioma with even minimal asbestos exposure. Click here to read the complete story ... of Hawaii Cancer Center, Cedars Sinai Medical Center, and New York University exposed mice ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. ... been retained to lead a national chief nursing officer recruitment for ... firms in the healthcare industry, B. E. Smith has recently placed more than ...
Breaking Medicine News(10 mins):Health News:MillionaireMatchapp.com Publishes the Best Millionaire Dating App and Official Dating Site Reviews 2015 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... method to diagnose lung disease that is based on the ... led a team of researchers in using a sensor employed ... ,The sensor, called a microDMxTM sensor was developed ... detect "unhealthy" molecules emanating from the breath of a patient. ...
... of Quinolone antibiotics for eardrum perforations has been ... disease than the use of systemic antibiotics//. Dr. ... in the Liverpool School of Tropical Medicine, UK ... Cochrane Library that topical quinolone are better than ...
... aspirin to prevent heart problem have increased tremendously//. ... of Public Health (GSPH) and others conducted the study and ... African Americans and diabetics do not opt for aspirin therapy. ... and Europe measured regular use of aspirin among 2,163 African ...
... Griffiths, Ph.D., professor of geriatric medicine, University of Pittsburgh School ... the reduced activity of the orbitofrontal cortex of the brain. ... issue of the Journal of Urology. He studied the brain ... He analyzed the brain activity of 6 normal people and ...
... of breast cancer cases in the UK. As many as ... ductal carcinoma// in situ (DCIS) during 2002. The Cancer Research ... therapy drugs are capable of preventing the recurrence of the ... being studied. The DCIS is considered a pre-cancerous condition, which ...
... fertility kit, which is termed as the Plan Ahead kit comes ... and helps them to decide about their pregnancy//. The kit ... completing all the necessary tests. It gives them a clear view ... and compares it with a standard levels. The results help the ...
Cached Medicine News:Health News:Sensor Can Detect "Unhealthy" Molecules In Breath 2Health News:New fertility kit, analyzes the woman's ability to conceive 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: